Filing Flows › Theriva Biologics (TOVX) › Q1 2026
Theriva Biologics (TOVX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Theriva Biologics (TOVX) reported revenue of $300K for the first quarter 2026 (Q1 2026). Operating margin was -709.0%, net loss $2.0M (681.3% of revenue).
Theriva Biologics, Q1 2026: revenue $300K, operating margin -709.0%, net loss $2.0M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $300K | — | — |
| Operating profit | −$2.1M | — | — |
| Net earnings | −$2.0M | — | — |
| Operating cash flow | −$2.5M | — | — |
What changed
Revenue was $300K in Q1 2026.
Operating costs exceeded revenue by $2.1M, an operating margin of -709.0%. The quarter ended with a net loss of $2.0M.
Operating cash flow was −$2.5M. Non-cash charges added back $24K of depreciation and amortization and $135K of share-based compensation. Working capital and other items used $571K.
Questions
What was Theriva Biologics' revenue in the first quarter 2026?
Theriva Biologics (TOVX) reported revenue of $300K for the first quarter 2026 (Q1 2026).
Was Theriva Biologics profitable in the first quarter 2026?
Operating loss was $2.1M (-709.0% of revenue) and net loss $2.0M.
Source: Theriva Biologics 10-Q on SEC EDGAR.